![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Mayo Clinic Eli Lilly and Company |
|---|---|
| Information provided by: | Mayo Clinic |
| ClinicalTrials.gov Identifier: | NCT00587639 |
Purpose
The objective of this investigation is to examine the safety and feasibility of a series rTMS treatments (10 Hz; Left Dorsolateral Prefrontal Cortex), with a Neuronetics Model 2100 CRS Repetitive Transcranial Magnetic Stimulation (rTMS) system as adjuvant treatment for depression in adolescent subjects.
| Condition | Intervention |
|---|---|
|
Depression |
Device: rTMS Treatment |
| Arms | Assigned Interventions |
|---|---|
|
Active Treatment: Active Comparator
All subjects will have active rTMS treatment (10Hz, L-DLPFC - 3,000 Stimulations/treatment)
|
Device: rTMS Treatment
Active rTMS treatment.
|
High frequency rTMS applied to the left dorsolateral prefrontal cortex (L-DLPFC) has been shown to have an antidepressant effect. Initial studies comparing electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) suggest that rTMS has been as effective as ECT in treating non-psychotic depression. Given the high degree of ongoing dysfunction in depressed adolescents despite optimization of treatment with antidepressant medications, new concerns regarding suicidal thoughts and behaviors in adolescents treated with antidepressant medications, and the more interventional nature of ECT, the use of rTMS as adjuvant therapy may be of significant clinical benefit. Thus far, research using rTMS to treat depression in adolescents has been limited. The primary aim of this study is to examine the safety and feasibility of using 10 Hz rTMS applied to the L-DLPFC as adjuvant treatment for depression in adolescents.
Eligibility
Inclusion Criteria:
SSRI Medications will include:
Exclusion Criteria:
Contacts and Locations| United States, Illinois | |
| Rush University | Recruiting |
| Chicago, Illinois, United States, 60612 | |
| Contact: Natalie Forburger 219-588-0688 nforburger@sbcglobal.net | |
| Principal Investigator: Phillip G Janicak, MD | |
| Sub-Investigator: Patricia M Meaden, PhD | |
| Sub-Investigator: Sheila M Dowd, PhD | |
| Sub-Investigator: Jeff Rado, MD | |
| Sub-Investigator: Amer Smajkic, MD | |
| Principal Investigator: Louis J Kraus, MD | |
| Sub-Investigator: Hollie Sobel, PhD | |
| Sub-Investigator: Louis F Fogg, PhD | |
| United States, Minnesota | |
| Mayo Clinic | Recruiting |
| Rochester, Minnesota, United States, 55905 | |
| Contact: Christopher A Wall, M.D. 507-284-3758 wall.chris@mayo.edu | |
| Contact: Shirlene M Sampson, M.D. 507-284-3758 sampson.shirlene@mayo.edu | |
| Principal Investigator: Christopher A Wall, M.D. | |
| Principal Investigator: Shirlene M Sampson, M.D. | |
| Sub-Investigator: Leslie A Sim, Ph.D. | |
| Sub-Investigator: Brett A Koplin, M.D. | |
| Sub-Investigator: Donald E McAlpine, M.D. | |
| Sub-Investigator: Simon Kung, M.D. | |
| United States, Texas | |
| University of Texas Southwestern | Recruiting |
| Dallas, Texas, United States, 75390 | |
| Contact: Paul E Croarkin, DO 214-456-6888 paul.croarkin@childrens.com | |
| Principal Investigator: Paul E Croarkin, DO | |
| Principal Investigator: Mustafa M Husain, MD | |
| Sub-Investigator: Frank A Kozel, MD | |
| Sub-Investigator: Graham J Emslie, MD | |
| Sub-Investigator: Peter L Stavinoha, PhD | |
| Principal Investigator: | Shirlene M. Sampson, M.D. | Mayo Clinic |
| Principal Investigator: | Christopher A. Wall, M.D. | Mayo Clinic |
More Information